ProStrakan's primary strength is in its multidisciplinary staff of about 30 professionals in R&D, trained throughout Europe and the United States, whose expertise covers all aspects of research and development. The development function is based at Galashiels in Scotland.

ProStrakan's R&D management has a significant track record with a broad spread of expertise including R&D, product development and approvals in both big pharma and biotech environments.

ProStrakan currently has a wide portfolio of products in development and registration:

• Rectogesic (pain associated with chronic anal fissure) - US
• Tostran (hypogonadism) - US
• Rapinyl (cancer breakthrough pain) - Registration, EU
• Xomolix (post operative nausea and vomiting) - Registration, EU
• Sancuso (chemotherapy induced nausea and vomiting) - Registration
• Estradiol glucoside (HRT) - PII
• Topical NO (onychomycosis) - PII
• Topical anti-androgen (alopecia, acne) - PII
• Testosterone glucoside (hypogonadism) - PI
• TIMES 2 - Effect of transdermal testosterone replacement (Tostran) in hypogonadal men with either metabolic syndrome or type II diabetes mellitus - PIII